Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Sensors (Basel, Switzerland)|March 13, 2024
Deep Reinforcement Learning-Based Energy Consumption Optimization for Peer-to-Peer (P2P) Communication in Wireless Sensor NetworksJinyu Yuan, Jingyi Peng, Qing Yan, et al.
Environmental Science and Pollution Research International|December 1, 2023
Strong metal support interaction (SMSI) and MoO3 synergistic effect of Pt-based catalysts on the promotion of CO activity and sulfur resistanceJunda He, Jian Li, Zehui Yu, et al.
The Science of the Total Environment|November 10, 2020
A novel fluorescent probe based on N, B, F co-doped carbon dots for highly selective and sensitive determination of sulfathiazoleLetian Chen, Yongli Liu, Guohao Cheng, et al.
Journal of Molecular Cell Biology|December 9, 2022
DNA/RNA helicase DHX36 is required for late stages of spermatogenesisKejia Zhang, Tianxin Zhang, Yujie Zhang, et al.
Advances in Therapy|February 17, 2009
Pharmacokinetics of digoxin in healthy subjects receiving taranabant, a novel cannabinoid-1 receptor inverse agonistAndrew E Denker, Gaetano Morelli, Laura K Vessey, et al.
Journal of Clinical Pharmacology|October 22, 2008
Influence of taranabant, an orally active, highly selective, potent cannabinoid-1 receptor (CB1R) inverse agonist, on ethinyl estradiol and norelgestromin plasma pharmacokineticsJules I Schwartz, Stephanie Dunbar, Jinyu Yuan, et al.
Cancer|September 24, 2010
Sunitinib in metastatic renal cell carcinoma patients with brain metastasesMartin E Gore, Subramanian Hariharan, Camillo Porta, et al.
Advances in Therapy|November 8, 2008
Influence of taranabant, a cannabinoid-1 receptor inverse agonist, on pharmacokinetics and pharmacodynamics of warfarinJules I Schwartz, Stephanie Dunbar, Jinyu Yuan, et al.
Asia-Pacific Journal of Clinical Oncology|March 1, 2014
Sunitinib in metastatic renal cell carcinoma: an ethnic Asian subpopulation analysis for safety and efficacySe-Hoon Lee, Yung-Jue Bang, Paul Mainwaring, et al.
Cancer|September 8, 2011
Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinomaCarlos H Barrios, David Hernandez-Barajas, Michael P Brown, et al.
Pageof 2